
Innovative Bispecific Antibody ALGAPV-527 Meets Key Trial Endpoints in Phase 1 Solid Tumor Study
Aptevo Therapeutics and Alligator Bioscience Report Favorable Safety and Efficacy Data for ALG.APV-527 Positive Results in Phase 1 Trial Aptevo Therapeutics and Alligator Bioscience have announced encouraging preliminary data from their Phase 1 trial of ALG.APV-527, a novel bispecific antibody designed for the treatment of solid tumors expressing tumor antigen 5T4. The data presented at…